Epilepsy, hyperalgesia, impaired memory, and loss of pre- and postsynaptic GABAB responses in mice lacking GABAB(1)

被引:417
作者
Schuler, V
Lüscher, C
Blanchet, C
Klix, N
Sansig, G
Klebs, K
Schmutz, M
Heid, J
Gentry, C
Urban, L
Fox, A
Spooren, W
Jaton, AL
Vigouret, JM
Pozza, M
Kelly, PH
Mosbacher, J
Froestl, W
Käslin, E
Korn, R
Bischoff, S
Kaupmann, K
van der Putten, H
Bettler, B [1 ]
机构
[1] Novartis Pharma AG, TA Nervous Syst, CH-4002 Basel, Switzerland
[2] Novartis Inst Med Sci, London WC1E 6B9, England
[3] Univ Geneva, Dept Pharmacol APSIC, CH-1211 Geneva, Switzerland
[4] Univ Geneva, Dept Physiol, CH-1211 Geneva 4, Switzerland
[5] Univ Geneva, Dept Neurol, CH-1211 Geneva 4, Switzerland
关键词
D O I
10.1016/S0896-6273(01)00345-2
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
GABA(B) (gamma -aminobutyric acid type B) receptors are important for keeping neuronal excitability under control. Cloned GABA(B) receptors do not show the expected pharmacological diversity of native receptors and it is unknown whether they contribute to pre- as well as postsynaptic functions. Here, we demonstrate that Balb/c mice lacking the GABA(B(1)) subunit are viable, exhibit spontaneous seizures, hyperalgesia, hyperlocomotor activity, and memory impairment. Upon GABA(B) agonist application, null mutant mice show neither the typical muscle relaxation, hypothermia, or delta EEG waves. These behavioral findings are paralleled by a loss of all biochemical and electrophysiological GABA(B) responses in null mutant mice. This demonstrates that GABA(B(1)) is an essential component of pre- and postsynaptic GABA(B) receptors and casts doubt on the existence of proposed receptor subtypes.
引用
收藏
页码:47 / 58
页数:12
相关论文
共 54 条
[1]   AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration [J].
AbdAlla, S ;
Lother, H ;
Quitterer, U .
NATURE, 2000, 407 (6800) :94-98
[2]   TIME-DOSE RELATIONSHIPS FOR LOCOMOTOR ACTIVITY EFFECTS OF MORPHINE AFTER ACUTE OR REPEATED TREATMENT [J].
BABBINI, M ;
DAVIS, WM .
BRITISH JOURNAL OF PHARMACOLOGY, 1972, 46 (02) :213-&
[3]   Comparative in vivo and in vitro studies with the potent GABA(B) receptor antagonist, CGP 56999A [J].
Badran, S ;
Schmutz, M ;
Olpe, HR .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 333 (2-3) :135-142
[4]   γ-aminobutyric acid type B receptor splice variant proteins GBR1a and GBR1b are both associated with GBR2 in situ and display differential regional and subcellular distribution [J].
Benke, D ;
Honer, M ;
Michel, C ;
Bettler, B ;
Mohler, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (38) :27323-27330
[5]  
Bischoff S, 1999, J COMP NEUROL, V412, P1
[6]   GABA(B) RECEPTOR ANTAGONISTS - FROM SYNTHESIS TO THERAPEUTIC APPLICATIONS [J].
BITTIGER, H ;
FROESTL, W ;
MICKEL, SJ ;
OLPE, HR .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1993, 14 (11) :391-394
[7]   MULTIPLE GABA(B) RECEPTORS [J].
BONANNO, G ;
RAITERI, M .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1993, 14 (07) :259-261
[8]   Hippocampal long-term potentiation and spatial learning in the rat: Effects of GABA(B) receptor blockade [J].
Brucato, FH ;
Levin, ED ;
Mott, DD ;
Lewis, DV ;
Wilson, WA ;
Swartzwelder, HS .
NEUROSCIENCE, 1996, 74 (02) :331-339
[9]  
Calver AR, 2001, J NEUROSCI, V21, P1203
[10]   MECHANISM OF MU-OPIOID RECEPTOR-MEDIATED PRESYNAPTIC INHIBITION IN THE RAT HIPPOCAMPUS IN-VITRO [J].
CAPOGNA, M ;
GAHWILER, BH ;
THOMPSON, SM .
JOURNAL OF PHYSIOLOGY-LONDON, 1993, 470 :539-558